Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance
Crossref DOI link: https://doi.org/10.1186/s40880-015-0029-3
Published Online: 2015-07-08
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Xu, Xiao
